1. Home
  2. CLRO vs TCRT Comparison

CLRO vs TCRT Comparison

Compare CLRO & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ClearOne Inc. (DE)

CLRO

ClearOne Inc. (DE)

SELL

Current Price

$4.76

Market Cap

8.7M

Sector

Technology

ML Signal

SELL

Logo Alaunos Therapeutics Inc.

TCRT

Alaunos Therapeutics Inc.

SELL

Current Price

$1.62

Market Cap

7.8M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
CLRO
TCRT
Founded
1983
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Radio And Television Broadcasting And Communications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.7M
7.8M
IPO Year
2018
2025

Fundamental Metrics

Financial Performance
Metric
CLRO
TCRT
Price
$4.76
$1.62
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 6.4M
1.6M
Earning Date
11-10-2026
11-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 24.66
EPS
★ N/A
N/A
Revenue
★ $46,067,000.00
$15,900,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 11.59
N/A
52 Week Low
$1.62
$0.72
52 Week High
$16.50
$4.50

Technical Indicators

Market Signals
Indicator
CLRO
TCRT
Relative Strength Index (RSI) 53.90 44.64
Support Level $3.32 $1.61
Resistance Level $5.91 $2.09
Average True Range (ATR) 0.87 0.17
MACD -0.05 -0.07
Stochastic Oscillator 37.91 10.16

Price Performance

Historical Comparison
CLRO
TCRT

About CLRO ClearOne Inc. (DE)

ClearOne Inc is currently engaged in activities that consist solely of fulfilling warranty and technical support obligations on legacy products, evaluating potential Strategic Transactions, managing and liquidating remaining assets of the company's legacy operating business, collecting accounts receivable and recovering prepaid assets, satisfying outstanding liabilities, and maintaining public-company compliance.

About TCRT Alaunos Therapeutics Inc.

Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.

Share on Social Networks: